Equal yet different: a comparative characterization of Ruthenibacterium lactatiformans and Faecalibacterium prausnitzii

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The gut microbiota plays a key role in maintaining human homeostasis. Of particular interest are 2 bacterial species of the family Oscillospiraceae: the well-studied Faecalibacterium prausnitzii, with proven anti-inflammatory properties, and the recently described Ruthenibacterium lactatiformans, whose functional potential remains insufficiently investigated. Despite their phylogenetic proximity, these species differ substantially in metabolic properties, associations with pathological conditions, and probiotic potential. The work aimed to conduct a comparative analysis of the characteristics of F. prausnitzii and R. lactatiformans and their interactions with the host, as well as to summarize data on possible mechanisms underlying their influence on the development of a wide range of diseases, including inflammatory bowel diseases, cardiovascular, metabolic, neurologic, and oncologic diseases.

Studies demonstrate that reduced abundance of F. prausnitzii serves as a reliable biomarker of dysbiosis and is associated with chronic inflammatory, autoimmune, and metabolic diseases. The protective role of this bacterium is primarily related to butyrate production and immunomodulation. In contrast to F. prausnitzii, associations of R. lactatiformans with pathological conditions are inconsistent. Increased abundance of this species correlates with both pathological states (stroke, active multiple sclerosis) and periods of clinical remission in certain diseases. At the same time, in experimental models, R. lactatiformans demonstrates protective, particularly metabolic, properties.

The decrease in F. prausnitzii abundance under pathological conditions is likely explained by its sensitivity to environmental changes such as tissue acidosis and oxidative stress. In contrast, R. lactatiformans, owing to greater metabolic plasticity (ability to produce lactate and acetate) and relative aerotolerance, is capable of adapting to these unfavorable conditions.

In conclusion, we support the hypothesis that the observed changes may reflect a dynamic dysbiotic shift and potential synergism rather than competition: R. lactatiformans, acting as an adaptive substrate supplier, may contribute to restoration of conditions favorable for subsequent colonization by butyrate-producing bacteria such as F. prausnitzii. This opens new perspectives for the development of probiotic strategies based on synergistic bacterial consortia.

Full Text

Restricted Access

About the authors

Milana S. Das

Peoples’ Friendship University of Russia (RUDN University)

Author for correspondence.
Email: milanadas@yandex.ru
ORCID iD: 0000-0001-7637-9879
SPIN-code: 5956-7634

MD

Russian Federation, Moscow

Irina V. Podoprigora

Peoples’ Friendship University of Russia (RUDN University)

Email: podoprigora-iv@rudn.ru
ORCID iD: 0000-0003-4099-2967
SPIN-code: 7255-4454

MD, Cand. Sci. (Medicine), Assistant Professor

Russian Federation, Moscow

Natalia V. Yashina

Peoples’ Friendship University of Russia (RUDN University)

Email: yashina-nv@rudn.ru
ORCID iD: 0000-0003-1372-5257
SPIN-code: 4340-5962

Cand. Sci. (Biology), Assistant Professor

Russian Federation, Moscow

Alexsander N. Senyagin

Peoples’ Friendship University of Russia (RUDN University)

Email: senyagin-an@rudn.ru
ORCID iD: 0000-0002-4981-0149
SPIN-code: 2658-3063

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

Anatoly K. Tokmalaev

Peoples’ Friendship University of Russia (RUDN University)

Email: tokmalaev-ak@rudn.ru
ORCID iD: 0000-0001-7046-0799
SPIN-code: 1650-0831

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Valentina S. Orlova

Peoples’ Friendship University of Russia (RUDN University)

Email: orlova-vs@rudn.ru
ORCID iD: 0000-0001-9178-5736
SPIN-code: 8078-0470

Dr. Sci. (Biology), Professor

Russian Federation, Moscow

Boris A. Efimov

Pirogov Russian National Research Medical University

Email: efimov_ba@mail.ru
ORCID iD: 0009-0003-8879-6516
SPIN-code: 3056-5899

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

References

  1. Chang C, Yuan X, Zhang X, et al. Gastrointestinal microbiome and multiple health outcomes: umbrella review. Nutrients. 2022;14(18):3726. doi: 10.3390/nu14183726 EDN: JSGPTN
  2. Fujimura KE, Slusher NA, Cabana MD, Lynch SV. Role of the gut microbiota in defining human health. Expert Rev Anti Infect Ther. 2010;8(4):435–454. doi: 10.1586/eri.10.14
  3. Sen T, Thummer RP. The impact of human microbiotas in hematopoietic stem cell and organ transplantation. Front Immunol. 2022;13:932228. doi: 10.3389/fimmu.2022.932228 EDN: GRMLKR
  4. Yoo S, Jung SC, Kwak K, Kim JS. The role of prebiotics in modulating gut microbiota: implications for human health. Int J Mol Sci. 2024;25(9):4834. doi: 10.3390/ijms25094834 EDN: GXBNEQ
  5. Zhu B, Edwards DJ, Spaine KM, et al. The association of maternal factors with the neonatal microbiota and health. Nat Commun. 2024;15(1):5260. doi: 10.1038/s41467-024-49160-w EDN: GJLCTW
  6. De Filippis F, Paparo L, Nocerino R, et al. Specific gut microbiome signatures and the associated pro-inflamatory functions are linked to pediatric allergy and acquisition of immune tolerance. Nat Commun. 2021;12(1):5958. doi: 10.1038/s41467-021-26266-z EDN: JYGBCJ
  7. Marcos-Fernández R, Riestra S, Alonso-Arias R, et al. Immunomagnetic capture of Faecalibacterium prausnitzii selectively modifies the fecal microbiota and its immunomodulatory profile. Microbiol Spectr. 2023;11(1):e0181722. doi: 10.1128/spectrum.01817-22 EDN: XCIMEE
  8. Zhao L, Grimes SM, Greer SU, et al. Characterization of the consensus mucosal microbiome of colorectal cancer. NAR Cancer. 2021;3(4):zcab049. doi: 10.1093/narcan/zcab049 EDN: EYSHZV
  9. Lopez-Siles M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. ISME J. 2017;11(4):841–852. doi: 10.1038/ismej.2016.176 EDN: YWLKON
  10. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731–16736. doi: 10.1073/pnas.0804812105
  11. Fitzgerald CB, Shkoporov AN, Sutton TDS, et al. Comparative analysis of Faecalibacterium prausnitzii genomes shows a high level of genome plasticity and warrants separation into new species-level taxa. BMC Genomics. 2018;19(1):931. doi: 10.1186/s12864-018-5313-6 EDN: MHBOSS
  12. Shkoporov AN, Chaplin AV, Shcherbakova VA, et al. Ruthenibacterium lactatiformans gen. nov., sp. nov., an anaerobic, lactate-producing member of the family Ruminococcaceae isolated from human faeces. Int J Syst Evol Microbiol. 2016;66(8):3041–3049. doi: 10.1099/ijsem.0.001143 EDN: XFKZPB
  13. Rampelli S, Turroni S, Mallol C, et al. Components of a Neanderthal gut microbiome recovered from fecal sediments from El Salt. Commun Biol. 2021;4(1):169. doi: 10.1038/s42003-021-01689-y EDN: RIRPRW
  14. Prausnitz C. Der Bacillus mucosus anaerobius. Zentralbl Bakteriol Parasitenkd Infektionskr Hyg Abt I Orig. 1922;89:126–132.
  15. Hauduroy P, Ehringer G, Guillot G, et al. Dictionnaire des bactéries pathogènes: pour l’homme, les animaux et les plantes. Paris: Masson; 1937.
  16. Cato EP, Salmon CW, Moore WEC. Fusobacterium prausnitzii (Hauduroy et al.) Moore and Holdeman: emended description and designation of neotype strain. Int J Syst Bacteriol. 1974;24(2):225–229.
  17. Collins MD, Lawson PA, Willems A, et al. The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J Syst Evol Microbiol. 1994;44(4):812–826.
  18. Duncan SH, Hold GL, Harmsen HJM, et al. Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. Int J Syst Evol Microbiol. 2002;52(Pt 6):2141–2146. doi: 10.1099/00207713-52-6-2141
  19. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–180. doi: 10.1038/nature09944
  20. Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014;38(5):996–1047. doi: 10.1111/1574-6976.12075
  21. Kumar S, Stecher G, Suleski M, et al. MEGA12: molecular evolutionary genetic analysis version 12 for adaptive and green computing. Mol Biol Evol. 2024;41(12):msae263. doi: 10.1093/molbev/msae263 EDN: XJLZTL
  22. Sumiyoshi S, Hamaguchi S, Kimura K, et al. Ruthenibacterium lactatiformans isolated from a human blood culture: a first report. BMC Infect Dis. 2024;24(1):699. doi: 10.1186/s12879-024-09606-4 EDN: YMBXJT
  23. Hashimoto Y, Hisatsune J, Suzuki M, et al. Elucidation of host diversity of the VanD-carrying genomic islands in enterococci and anaerobes. JAC Antimicrob Resist. 2022;4(1):dlab189. doi: 10.1093/jacamr/dlab189 EDN: IVHFHN
  24. Blanco G, Sánchez B, Fdez-Riverola F, et al. In silico approach for unveiling the glycoside hydrolase activities in Faecalibacterium prausnitzii through a systematic and integrative large-scale analysis. Front Microbiol. 2019;10:517. doi: 10.3389/fmicb.2019.00517 EDN: WZMXEC
  25. Geng P, Zhao N, Zhou Y, et al. Faecalibacterium prausnitzii regulates carbohydrate metabolic functions of the gut microbiome in C57BL/6 mice. Gut Microbes. 2025;17(1):2455503. doi: 10.1080/19490976.2025.2455503 EDN: OTULEU
  26. Dogra SK, Dardinier A, Mainardi F, et al. Application of computational data modeling to a large-scale population cohort assists the discovery of inositol as a strain-specific substrate for Faecalibacterium prausnitzii. Nutrients. 2023;15(6):1311. doi: 10.3390/nu15061311 EDN: EILRXH
  27. Huang YJ, Lewis CA, Wright C, et al. Faecalibacterium prausnitzii A2-165 metabolizes host- and media-derived chemicals and induces transcriptional changes in colonic epithelium in GuMI human gut microphysiological system. Microbiome Res Rep. 2024;3(3):30. doi: 10.20517/mrr.2024.14 EDN: HPLDND
  28. Guo Y, Crnkovic CM, Won KJ, et al. Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites. Drug Metab Dispos. 2019;47(3):194–202. doi: 10.1124/dmd.118.084772
  29. Auger S, Kropp C, Borras-Nogues E, et al. Intraspecific diversity of microbial anti-inflammatory molecule (MAM) from Faecalibacterium prausnitzii. Int J Mol Sci. 2022;23(3):1705. doi: 10.3390/ijms23031705 EDN: RRLTQZ
  30. Miquel S, Leclerc M, Martin R, et al. Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. mBio. 2015;6(2):e00300-15. doi: 10.1128/mBio.00300-15 EDN: UOUOOR
  31. Hammond TC, Powell E, Green SJ, et al. Functional recovery outcomes following acute stroke is associated with abundance of gut microbiota related to inflammation, butyrate and secondary bile acid. Front Rehabil Sci. 2022;3:1017180. doi: 10.3389/fresc.2022.1017180 EDN: IYPXUA
  32. Li W, Li H, Wang S, et al. Regional pattern and signatures of gut microbiota in rural residents with coronary heart disease: A metagenomic analysis. Front Cell Infect Microbiol. 2022;12:1007161. doi: 10.3389/fcimb.2022.1007161 EDN: QPTVDE
  33. Xu H, Zhao H, Fan D, et al. Interactions between gut microbiota and immunomodulatory cells in rheumatoid arthritis. Mediators Inflamm. 2020;2020:1430605. doi: 10.1155/2020/1430605 EDN: VNNFJT
  34. Lee JY, Mannaa M, Kim Y, et al. Comparative analysis of fecal microbiota composition between rheumatoid arthritis and osteoarthritis patients. Genes (Basel). 2019;10(10):748. doi: 10.3390/genes10100748 EDN: ZYRXDU
  35. Clos-Garcia M, Ahluwalia TS, Winther SA, et al. Multiomics signatures of type 1 diabetes with and without albuminuria. Front Endocrinol (Lausanne). 2022;13:1015557. doi: 10.3389/fendo.2022.1015557 EDN: TKDFCB
  36. Trivieri N, Pracella R, Cariglia MG, et al. BRAFV600E mutation impinges on gut microbial markers defining novel biomarkers for serrated colorectal cancer effective therapies. J Exp Clin Cancer Res. 2020;39(1):285. doi: 10.1186/s13046-020-01801-w EDN: WOEOXG
  37. Sabater C, Calvete-Torre I, Ruiz L, Margolles A. Arabinoxylan and pectin metabolism in Crohn’s disease microbiota: An in silico study. Int J Mol Sci. 2022;23(13):7093. doi: 10.3390/ijms23137093 EDN: QKOKBI
  38. Jangi S, Zhao N, Hsia K, et al. Specific bacterial co-abundance groups are associated with inflammatory status in patients with ulcerative colitis. J Crohns Colitis. 2025;19(1):jjae125. doi: 10.1093/ecco-jcc/jjae125 EDN: KNQPRH
  39. Dias BDC, Lamarca AP, Machado DT, et al. Metabolic pathways associated with Firmicutes prevalence in the gut of multiple livestock animals and humans. Anim Microbiome. 2025;7(1):20. doi: 10.1186/s42523-025-00379-y EDN: DUFDDA
  40. Eckenberger J, Butler JC, Bernstein CN, et al. Interactions between medications and the gut microbiome in inflammatory bowel disease. Microorganisms. 2022;10(10):1963. doi: 10.3390/microorganisms10101963 EDN: KOYAHZ
  41. Testerman T, Li Z, Galuppo B, et al. Insights from shotgun metagenomics into bacterial species and metabolic pathways associated with NAFLD in obese youth. Hepatol Commun. 2022;6(8):1962–1974. doi: 10.1002/hep4.1944 EDN: CRTNEY
  42. Wu F, Guo Y, Wang Y, et al. Effects of long-term fasting on gut microbiota, serum metabolome, and their association in male adults. Nutrients. 2024;17(1):35. doi: 10.3390/nu17010035 EDN: BIONNE
  43. Kovtun AS, Averina OV, Angelova IY, et al. Alterations of the composition and neurometabolic profile of human gut microbiota in major depressive disorder. Biomedicines. 2022;10(9):2162. doi: 10.3390/biomedicines10092162 EDN: WVZGWF
  44. Cox LM, Maghzi AH, Liu S, et al. Gut microbiome in progressive multiple sclerosis. Ann Neurol. 2021;89(6):1195–1211. doi: 10.1002/ana.26084 EDN: AFFKGG
  45. Zhou X, Baumann R, Gao X, et al. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell. 2022;185(19):3467–3486.e16. doi: 10.1016/j.cell.2022.08.021 EDN: JFOATQ
  46. Becker A, Schmartz GP, Gröger L, et al. Effects of resistant starch on symptoms, fecal markers, and gut microbiota in Parkinson’s disease - The RESISTA-PD trial. Genomics Proteomics Bioinf. 2022;20(2):274–287. doi: 10.1016/j.gpb.2021.08.009 EDN: ULAIYN
  47. Wallen ZD, Demirkan A, Twa G, et al. Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms. Nat Commun. 2022;13(1):6958. doi: 10.1038/s41467-022-34667-x
  48. Yay E, Yilmaz M, Toygar H, et al. Oral and gut microbial profiling in periodontitis and Parkinson’s disease. J Oral Microbiol. 2024;16(1):2331264. doi: 10.1080/20002297.2024.2331264 EDN: QSAGBF
  49. Liang S, Mao Y, Liao M, et al. Gut microbiome associated with APC gene mutation in patients with intestinal adenomatous polyps. Int J Biol Sci. 2020;16(1):135–146. doi: 10.7150/ijbs.37399 EDN: JVVYIS
  50. Wei Z, Cao S, Liu S, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients’ survival? A pilot study on relevant mechanism. Oncotarget. 2016;7(29):46158–46172. doi: 10.18632/oncotarget.10064 EDN: WSHXMH
  51. Jia W, Whitehead RN, Griffiths L, et al. Is the abundance of Faecalibacterium prausnitzii relevant to Crohn’s disease? FEMS Microbiol Lett. 2010;310(2):138–144. doi: 10.1111/j.1574-6968.2010.02057.x EDN: NZHSDD
  52. Mclellan P, Auger S, Goudiaby MT, et al. Faecalibacterium diversity in the gut microbiome of Crohn’s disease patients. United European Gastroenterol J. 2025;13(8):1480–1490. doi: 10.1002/ueg2.70023 EDN: BIMWZB
  53. Lopez-Siles M, Khan TM, Duncan SH, et al. Cultured representatives of two major phylogroups of human colonic Faecalibacterium prausnitzii can utilize pectin, uronic acids, and host-derived substrates for growth. Appl Environ Microbiol. 2012;78(2):420–428. doi: 10.1128/AEM.06858-11
  54. Chen SJ, Zhang DY, Wu X, et al. Washed microbiota transplantation for Crohn’s disease: A metagenomic, metatranscriptomic, and metabolomic-based study. World J Gastroenterol. 2024;30(11):1572–1587. doi: 10.3748/wjg.v30.i11.1572 EDN: ZQAJFF
  55. Basha OM, Hafez RA, Salem SM, et al. Impact of gut microbiome alteration in ulcerative colitis patients on disease severity and outcome. Clin Exp Med. 2023;23(5):1763–1772. doi: 10.1007/s10238-022-00917-x EDN: ZGEJBY
  56. Xu J, Liang R, Zhang W, et al. Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression. J Diabetes. 2020;12(3):224–236. doi: 10.1111/1753-0407.12986
  57. Chasov V, Gilyazova E, Ganeeva I, et al. Gut microbiota modulation: a novel strategy for rheumatoid arthritis therapy. Biomolecules. 2024;14(12):1653. doi: 10.3390/biom14121653 EDN: XAUQBS
  58. Vural M, Gilbert B, Üstün I, et al. Mini-review: human microbiome and rheumatic diseases. Front Cell Infect Microbiol. 2020;10:491160. doi: 10.3389/fcimb.2020.491160 EDN: NDUHNO
  59. Xu X, Zhou J, Xie H, et al. Immunomodulatory mechanisms of the gut microbiota and metabolites on regulatory T cells in rheumatoid arthritis. Front Immunol. 2025;16:1610254. doi: 10.3389/fimmu.2025.1610254 EDN: OJZIUJ
  60. Cui X, Ye L, Li J, et al. Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci Rep. 2018;8(1):635. doi: 10.1038/s41598-017-18756-2 EDN: YFTRZB
  61. Simadibrata DM, Auliani S, Widyastuti PA, et al. The gut microbiota profile in heart failure patients: A systematic review. J Gastrointestin Liver Dis. 2023;32(3):393–401. doi: 10.15403/jgld-4779 EDN: RFIIMA
  62. Zheng T, Meng C, Lv Z, et al. The critical role of Faecalibacterium prausnitzii in cardiovascular diseases. Rev Cardiovasc Med. 2025;26(3):26740. doi: 10.31083/RCM26740 EDN: WIRVXH
  63. Luo Y, Chang G, Yu G, et al. Unveiling the negative association of Faecalibacterium prausnitzii with ischemic stroke severity, impaired prognosis and pro-inflammatory markers. Heliyon. 2024;10(5):e26651. doi: 10.1016/j.heliyon.2024.e26651 EDN: ZVHCUF
  64. Moran-Ramos S, Macias-Kauffer L, López-Contreras BE, et al. A higher bacterial inward BCAA transport driven by Faecalibacterium prausnitzii is associated with lower serum levels of BCAA in early adolescents. Mol Med. 2021;27(1):108. doi: 10.1186/s10020-021-00371-7 EDN: MRVHGT
  65. Hensen T, Thiele I. Metabolic modeling links gut microbiota to metabolic markers of Parkinson’s disease. Gut Microbes. 2025;17(1):2554195. doi: 10.1080/19490976.2025.2554195 EDN: SGDEEA
  66. Rasoulian P, Akhgarjand C, Houjaghani H, et al. Gut dysbiosis in multiple sclerosis patients: a comparative analysis in fecal samples. Sci Rep. 2025;15(1):36009. doi: 10.1038/s41598-025-19998-1 EDN: QREUDN
  67. Knuesel T, Mohajeri MH. The role of the gut microbiota in the development and progression of major depressive and bipolar disorder. Nutrients. 2021;14(1):37. doi: 10.3390/nu14010037 EDN: CKNSZM
  68. Ma J, Sun L, Liu Y, et al. Alter between gut bacteria and blood metabolites and the anti-tumor effects of Faecalibacterium prausnitzii in breast cancer. BMC Microbiol. 2020;20(1):82. doi: 10.1186/s12866-020-01739-1 EDN: CMZSFO

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Simplified diagram of protective and destructive modulation of the intestinal mucosa by microbiota. Author: Milana Sergeevna Das, created using a licensed version of BioRender.com. SCFAs are short-chain fatty acids.

Download (1MB)
3. Fig. 2. Phylogenetic dendrogram reflecting evolutionary relationships based on 16S rRNA gene sequences. Construction and analysis were performed using the MEGA software package (version 12.0). For phylogenetic reconstruction, the maximum likelihood (ML) method was applied using the Tamura–Ney model of nucleotide sequence evolution. Statistical support for branching (nodes) was assessed using bootstrap analysis (1000 pseudo-replicates) [21]. Author: Milana Sergeevna Das.

Download (836KB)

Copyright (c) 2026 Eco-vector

License URL: https://eco-vector.com/for_authors.php#07

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80652 от 15.03.2021
. Учредитель ООО "Эко-Вектор Ай-Пи" (ОГРН 1157847215338).